🔴 GT Biopharma is trading 10.21% down today after its 1-for-25 reverse stock split took effect

GT Biopharma is trading 10.21% down at $5.41 after its 1-for-25 reverse stock split became effective on September 8, 2026.

• Nasdaq confirmed split-adjusted trading began at market open, and the CUSIP changed.
• Outstanding shares fell from approximately 45.1 million to 1.8 million.
• Broader markets are also weaker, but the reverse split is the primary explanation and clear company-specific catalyst; confidence is high because Nasdaq and the company’s SEC filing align.